Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV
To best of our knowledge, our findings provide the first large-cohort evidence of low-level p24 persistence during suppressive ART and suggest that ongoing p24 production may contribute to residual immune activation in treated PLWH.
Authors
- Heiko Jessen
- Antonia Büning
- Christoph Stephan (ORCID: https://orcid.org/0000-0003-3777-9006)
- Julia König
- Jürgen K. Rockstroh (ORCID: https://orcid.org/0000-0003-2858-3888)
- Trevor A. Crowell (ORCID: https://orcid.org/0000-0001-5947-265X)
- Jernej Pušnik (ORCID: https://orcid.org/0000-0002-5987-8606)
- Stefan Eßer (ORCID: https://orcid.org/0000-0002-3625-9650)
- Hendrik Streeck (ORCID: https://orcid.org/0000-0002-0335-6390)
- Enrico Richter (ORCID: https://orcid.org/0009-0008-7736-8053)
- Christoph Boesecke
- Thomas Bechtel
- Alfonso Casado
Institutions
- Goethe University Frankfurt (DE)
- Henry M. Jackson Foundation (US)
- University of Bonn (DE)
- University Hospital Bonn (DE)
- German Center for Infection Research (DE)
- Essen University Hospital (DE)
- University Hospital Frankfurt (DE)
- University of Duisburg-Essen (DE)
- Praxis (EE)
- Walter Reed Army Institute of Research (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1038/s43856-025-01261-3
- Citations
- 1
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.04
Funders
- U.S. Department of Defense
- Henry M. Jackson Foundation